Protalix BioTherapeutics (PLX) Operating Expenses (2010 - 2026)

Protalix BioTherapeutics has reported Operating Expenses for 17 years, with the latest figure at $5.8 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 24.38% year-over-year to $5.8 million in Q2 2026; TTM through Jun 2026 was $17.5 million, a 12.29% decrease from a year earlier, with the FY2025 full-year figure at $21.0 million, up 18.38% from the prior year.
• Operating Expenses was $5.8 million for Q2 2026 at Protalix BioTherapeutics, up from $1.3 million in the prior quarter.
• The five-year high for Operating Expenses was $11.9 million in Q1 2022, with the low at $1.3 million in Q1 2026.
• Average Operating Expenses over 5 years is $6.9 million, with a median of $7.3 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses soared 38.57% in 2025, then slumped 79.15% in 2026.
• Over 5 years, Operating Expenses stood at $8.7 million in 2022, then retreated by 16.87% to $7.2 million in 2023, then tumbled by 73.8% to $1.9 million in 2024, then soared by 38.57% to $2.6 million in 2025, then soared by 121.9% to $5.8 million in 2026.
• The last three Operating Expenses figures came in at $5.8 million (Q2 2026), $1.3 million (Q1 2026), and $2.6 million (Q4 2025), per Business Quant data.